Lifeboat Foundation

Genentech’s Gregory Rippon, M.D., associates a few different phrases with the challenging nature of Alzheimer’s disease drug development: “cautious optimism,” “steady progress,” “an exercise in per | Genentech has been working on gantenerumab for 20 years, and, while it’s tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.

CMS officials disagree with the FDA’s reasoning, and are likely worried about the cost of covering a medication for hundreds of thousands of beneficiaries who might seek the treatment if it was broadly covered by Medicare. While CMS’s concern for taxpayers is understandable, it’s the FDA — not CMS — that has the statutory authority and deep medical expertise to assess a drug for approval. And Aduhelm passed the FDA’s assessment.

CMS arguably overstepped the bounds of its authority. Its decision is a huge blow to millions of Americans living with Alzheimer’s and their families. They are the losers in CMS’s decision, not only from the severe restriction on access to Aduhelm but also from its chilling effect on the development of other disease-modifying agents for people with Alzheimer’s. If CMS won’t pay for a treatment after the FDA legally approves it, why should a company bother pursuing this pathway?

CMS’s decision will affect the exploration for new treatments for Alzheimer’s for years, just at the time when new drugs appear to be making progress against this terrible disease.

Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.

Summary: Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.

Source: University of Eastern Finland.

Frontotemporal dementia patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal symptoms, a new study from the University of Eastern Finland shows. This observation can facilitate differential diagnostics in frontotemporal dementia.

A team of scientists has discovered how working memory is “formatted”—a finding that enhances our understanding of how visual memories are stored.

“For decades researchers have wondered about the nature of the neural representations that support our working memory,” explains Clayton Curtis, professor of psychology and neural science at New York University and the senior author of the paper, which appears in the journal Neuron. “In this study, we used both experimental and analytical techniques to reveal the format of working memory representations in the brain.”

The ability to store information for brief periods of time, or “working memory,” is a building block for most of our higher cognitive processes, and its dysfunction is at the heart of a variety of psychiatric and neurologic symptoms, including schizophrenia.

A unprecedented global study of Alzheimer’s disease has uncovered an additional 42 genes that may affect a person’s risk of developing the disorder. Doctors hope to use that information to develop a more precise way to identify risk.

Coming off multiple country approvals for his “patent free” Covid vaccine, Scientist, Researcher, Author, Science Explainer, Dr. Peter Hotez, MD, Ph.D. Baylor College of Medicine, drops by for an episode of Progress, Potential, And Possibilities.

Dr. Peter J. Hotez, M.D., Ph.D. (https://peterhotez.org/), is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine (https://www.bcm.edu/people-search/peter-hotez-23229), where he is also Chief of the Section of Pediatric Tropical Medicine and the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics (https://www.texaschildrens.org/find-a-doctor/peter-jay-hotez-md-phd).

Continue reading “Dr. Peter J. Hotez — Baylor College of Medicine — Scientist, Researcher, Author, Science Explainer” »

Dr Fossel talking about dementia, telomeres, and clarifying some experimental myths.

Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital.
Program & apply to join: https://foresight.org/biotech-health-extension-program/

Continue reading “Michael Fossel | Aging: Understanding it, Reversing it” »

Santiago Ramón y Cajal, a Spanish physician from the turn of the 19^th century, is considered by most to be the father of modern neuroscience. He stared down a microscope day and night for years, fascinated by chemically stained neurons he found in slices of human brain tissue. By hand, he painstakingly drew virtually every new type of neuron he came across using nothing more than pen and paper. As the Charles Darwin for the brain, he mapped every detail of the forest of neurons that make up the brain, calling them the “butterflies of the brain”. Today, 200 years later, Blue Brain has found a way to dispense with the human eye, pen and paper, and use only mathematics to automatically draw neurons in 3D as digital twins. Math can now be used to capture all the “butterflies of the brain”, which allows us to use computers to build any and all the billons of neurons that make up the brain. And that means we are getting closer to being able to build digital twins of brains.

These billions of neurons form trillions of synapses – where neurons communicate with each other. Such complexity needs comprehensive neuron models and accurately reconstructed detailed brain networks in order to replicate the healthy and disease states of the brain. Efforts to build such models and networks have historically been hampered by the lack of experimental data available. But now, scientists at the EPFL Blue Brain Project using algebraic topology, a field of Math, have created an algorithm that requires only a few examples to generate large numbers of unique cells. Using this algorithm – the Topological Neuronal Synthesis (TNS), they can efficiently synthesize millions of unique neuronal morphologies.